By using molecular docking calculations against the acetylcholinesterase (AChE), butyrylcholinesterase (BChE), amyloid precursor protein (APP), and 42-residue beta-amyloid peptide (A), it was determined whether apigenin-7-glucoside (A7G) and luteolin-7-glucoside (L7G) could be used as multi-targeted agents in AD. This evidence concerns the gene APP and Alzheimer disease.